 | William Macias, MD, PhD
Lilly Research Laboratories
Eli Lilly and Company
Indianapolis, Indiana
Indianapolis, In USA Dr. William Macias is Senior Medical Director for the cardiovascular and acute care platform team at Eli Lilly and Company. In his role, Dr. Macias has worldwide responsibility for the clinical development of multiple compounds in cardiovascular and critical care medicine. Most recently, he oversaw the late phase clinical development, submission and registration of Xigris for the treatment of patients with severe sepsis. Since 1996, Dr. Macias has been involved in the design and conduct of Phase IIa, Phase IIb, Phase III and Phase IV studies of multiple compounds for the treatment of severe sepsis and acute coronary syndromes. Prior to joining Lilly, Dr. Macias was an Associate Professor of Medicine at Indiana University School of Medicine, Indianapolis, Indiana. As a board certified intensivist and nephrologist, he was medical director for the renal intensive care and acute dialysis units at Indiana University Hospital and fellowship director for the nephrology fellowship program. He received his fellowship training and residency training in Internal Medicine at Indiana University. He received the PhD degree in physiology in 1991 and the MD degree in 1983, both from Indiana University School of Medicine. |
